Abcuro, Inc., a clinical-stage biotechnology firm, has successfully closed a $66 million Series D financing round to advance its leading therapeutic candidate. The funding, led by New Leaf Venture Partners, will support a new clinical study for ulviprubart in treating inclusion body myositis (IBM). This investment aims to address a significant unmet need for patients with this progressive disease, for which no approved therapies exist.
Financing Details and Investor Confidence
The financing was spearheaded by existing investor New Leaf Venture Partners and saw robust participation from Abcuro's current backers. The syndicate included abrdn Inc., Bain Capital Life Sciences, and Samsara BioCapital. New investor Rock Springs Capital also joined the round, demonstrating broad confidence in the company's direction and its promising therapeutic pipeline.
Ron Hunt of New Leaf Venture Partners expressed strong support for the company's mission and its targeted approach. He highlighted the significant need for an approved IBM treatment and praised the Abcuro team's expertise. This continued investment reflects a shared conviction in ulviprubart's potential to target the cytotoxic T cells responsible for muscle destruction.
Advancing Ulviprubart for Inclusion Body Myositis
Proceeds from the Series D round are earmarked for a new, potentially registrational clinical study of ulviprubart. This first-in-class monoclonal antibody targets KLRG1, a receptor on cytotoxic T cells implicated in autoimmune conditions. The upcoming trial will specifically evaluate the therapy's efficacy in patients with less severe forms of inclusion body myositis.
Following discussions with the U.S. Food and Drug Administration, Abcuro plans to initiate the new study in the fourth quarter of 2026. The company anticipates reporting top-line results from the trial in the second half of 2028. Positive outcomes would pave the way for Abcuro to file a biologics license application, moving closer to commercialization.
Insights from Previous Clinical Studies
The decision to pursue this new trial is supported by data from the recent Phase 2/3 MUSCLE study. While the primary endpoint was not met with statistical significance, the results showed a clear trend toward slowing disease progression. These findings provided a strong rationale for further investigation in a more targeted patient population.
A pre-defined analysis within the MUSCLE study revealed encouraging results for patients with less severe IBM. In this subgroup, ulviprubart demonstrated a 50% slowing of disease progression, offering a strong signal of clinical benefit. The therapy also showed a favorable safety and tolerability profile, reinforcing its potential as a viable treatment option.
Expert Perspective and Market Need
Dr. Namita Goyal of the University of California, Irvine, commented on the promising data from the MUSCLE study. She emphasized ulviprubart's unique mechanism, which targets the KLRG1-expressing T cells believed to drive the disease. Dr. Goyal noted the clear slowing of disease progression in less severe cases offers genuine hope to patients.
Inclusion body myositis remains a debilitating condition affecting thousands worldwide with no approved treatments. The lack of therapeutic options creates a significant unmet medical need for effective and safe interventions. Abcuro's focused efforts with ulviprubart represent a dedicated attempt to fill this critical void in patient care.
The successful $66 million financing marks a pivotal moment for Abcuro and the development of ulviprubart. This capital enables the company to launch a targeted registrational study, building on encouraging previous data for less severe IBM patients. This advancement highlights strong investor confidence and represents a significant step forward in the quest for an approved therapy.